This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Life Sciences & Health Care

Shifting demographics. Shrinking margins. Evolving regulations. Rising R&D costs. There is little doubt that life sciences and healthcare companies face a significant range of challenges for the years ahead. To adapt effectively, these organisations must re-examine their underlying operational strategies and refine their business models.

With experience in working with life sciences and healthcare companies to navigate multiple complex regulatory and financial ecosystems and optimise marketing and distribution channels, Deloitte's professionals are able to help our clients improve their business processes and achieve effective compliance in order to strengthen both patient care and stakeholder value.

More Featured insights

  • Shaping the future: From meaningful use to meaningful user
    Shaping the future: From meaningful use to meaningful user
    With the recent release of Meaningful Use Stage 2 requirements, health care providers may feel increasing pressure on their organisations to achieve the stated goals in order to qualify for available incentive dollars.
  • Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Physician Payment Sunshine Act: Physicians and life sciences companies coming to terms with transparency?
    Calls for more transparency and disclosure of payments made by the life sciences industry to health care professionals are creating challenges and opportunities for all parties involved in the delivery of health care.
  • The next phase: Opportunities in China
    The next phase: Opportunities in China's pharmaceuticals market
    As the world's next great market for patented drugs, companies who might have hesitated before now see that China is moving past its phase as a supply market for ingredients and generic finished drugs, and on to a new phase as the world's second largest life sciences and health care market within this decade.

Contact our leader

Janson Yap
Southeast Asia Industry Leader
Life Sciences & Health Care

Learn more

  • ExternalURL
    Zero to Hero
    How Deloitte helped a pharma company start up global operations to deliver a potentially life-saving antiviral
  • ExternalURL
    Health Care industry megatrends
    A Deloitte Center for Health Solutions discussion
  • ExternalURL
    Measuring the return from Pharmaceutical innovation 2012
    Is R&D earning its investment?